HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study
暂无分享,去创建一个
M. Robb | A. Esber | L. Eller | H. Kibuuka | M. Millard | S. Khamadi | T. Crowell | Ezra Musingye | H. Gelderblom | L. Maganga | C. Polyak | V. Sing'oei | J. Owuoth | E. Bahemana | Y. Adamu | Francis Kiweewa | J. Maswai | M. Semwogerere | A. Tindikahwa | C. Kafeero | F. Cham | Babajide Keshinro | J. Ake | Domonique M. Reed | R. Namagembe | A. Nambuya
[1] M. Robb,et al. Noninfectious Comorbidity in the African Cohort Study (AFRICOS). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Bartlett,et al. Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania , 2017, PloS one.
[3] S. Billong,et al. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaoundé-Cameroon , 2017, PloS one.
[4] T. Klimkait,et al. When patients fail UNAIDS’ last 90 - the “failure cascade” beyond 90-90-90 in rural Lesotho, Southern Africa: a prospective cohort study , 2017, Journal of the International AIDS Society.
[5] A. Szymczak,et al. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics , 2017, Journal of the International AIDS Society.
[6] M. Gisslén,et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment , 2017, PloS one.
[7] C. Leen,et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study , 2017, The lancet. HIV.
[8] R. Wanyenze,et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.
[9] A. Wensing,et al. Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women , 2017, Journal of virus eradication.
[10] T. Quinn,et al. Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda. , 2016, AIDS research and human retroviruses.
[11] A. Sönnerborg,et al. Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90‐90‐90 continuum of HIV care targets , 2016, HIV medicine.
[12] P. Harrigan,et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort , 2016, BMC Infectious Diseases.
[13] Jennifer F Hoy,et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. , 2016, JAMA.
[14] N. Fullman,et al. Evaluating facility‐based antiretroviral therapy programme effectiveness: a pilot study comparing viral load suppression and retention rates , 2016, Tropical medicine & international health : TM & IH.
[15] J. Baeten,et al. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. , 2016, AIDS research and human retroviruses.
[16] Jessica G. Young,et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. , 2015, The lancet. HIV.
[17] A. Crampin,et al. A comparative analysis of national HIV policies in six African countries with generalized epidemics , 2015, Bulletin of the World Health Organization.
[18] J. Skarbinski,et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. , 2015, JAMA internal medicine.
[19] R. Kosgei,et al. Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland , 2015, PloS one.
[20] S. Strasser,et al. 90-90-90 – Charting a steady course to end the paediatric HIV epidemic , 2015, Journal of the International AIDS Society.
[21] H. Kibuuka,et al. Evaluation of treatment outcomes for patients on first‐line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses , 2015, HIV medicine.
[22] Yusnarida Eka Nizmi,et al. PERAN UNAIDS (THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS) DALAM PENANGANAN HIV/AIDS DI ZIMBABWE , 2015 .
[23] H. Xing,et al. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China , 2014, BMJ Open.
[24] J. Bartlett,et al. Association of First-Line and Second-Line Antiretroviral Therapy Adherence , 2014, Open forum infectious diseases.
[25] E. Poveda,et al. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response , 2014, AIDS.
[26] Sarah Fidler,et al. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis , 2014, AIDS.
[27] M. Peeters,et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] D. Zannou,et al. Predictive Factors of Plasma HIV Suppression during Pregnancy: A Prospective Cohort Study in Benin , 2013, PloS one.
[29] A. Hatzakis,et al. Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals. , 2013, AIDS research and human retroviruses.
[30] M. Arnedo,et al. Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate? , 2012, PloS one.
[31] D. Pillay,et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.
[32] K. White,et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial , 2012, The Lancet.
[33] T. F. Rinke de Wit,et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] A. Abimiku,et al. Update on HIV-1 diversity in Africa: a decade in review. , 2012, AIDS reviews.
[35] C. Sabin,et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 , 2012, HIV medicine.
[36] L. Held,et al. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] O. Kirk,et al. Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam , 2011, International journal of STD & AIDS.
[38] A. Wensing,et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.
[39] Hannah Green,et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] M. Cortina-Borja,et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] D. Pillay,et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. , 2002, The Journal of infectious diseases.
[42] C. Sabin,et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre , 2001, AIDS.
[43] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.